Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05036590
Other study ID # 2020-A00269-30
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 5, 2022
Est. completion date December 31, 2024

Study information

Verified date February 2024
Source Hôpital le Vinatier
Contact Romain REY, MD, PhD
Phone +33437915495
Email romain.rey@ch-le-vinatier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In psychiatry, caregiver burden is associated with excess physical and psychological morbidity in relatives of patients with schizophrenic disorders Single or multi-family psychoeducation for caregivers of patients with schizophrenic disorders or first episode psychosis has a direct benefit on the health of the caregiver and an indirect benefit on the health of the ill family member. It is associated with a reduction in the rate of relapse and re-hospitalization and with better compliance with treatment. For single-family psychoeducation, the number of caregivers to be treated to avoid re-hospitalization of the sick family member is 3. For caregivers, psychoeducation is accompanied by an improvement in knowledge of the disorders and coping strategies. Therefore, international recommendations recommend that psychoeducation for caregivers be systematic, early, and integrated into routine care. Currently, the organization of the French care system does not allow these recommendations to be met. In order to increase the use of psychoeducation in France, early interventions for caregivers must be offered systematically. The effectiveness of early psychoeducation for caregivers needs to be evaluated; only three randomized controlled trials are available in the literature and none have been conducted in France.


Description:

The BREFORM project proposes to train health professionals in an early psychoeducation program, the BREF program, in order to implement it in their structure, and to evaluate its impact on the burden of caregivers of users living with a first psychotic episode or a schizophrenic disorder. Regarding caregivers' outcomes: outcome measures will be assessed at baseline (visit 1, V1), 6 weeks (Visit 2, V2), 6 months (Visit 3, V3), 12 months (Visit 4, V4) after baseline in the active group and in the treatment as usual group Regarding patients' outcomes: outcome measures will be assessed at baseline and 12 months after baseline in the active group and in the treatment as usual group Regarding mental health professionals' outcomes: outcome measures will be assessed before, after and 16 months after the training course Regarding the psychiatric departments' outcomes: outcome measures will be assessed at baseline and 36 months after baseline


Recruitment information / eligibility

Status Recruiting
Enrollment 206
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - people over 18yo - first-degree relatives (parents, siblings, children) or spouse of the patient - primary caregiver of a patient with schizophrenic disorders or first psychotic episode (DSM5) - consenting to participate to the study Exclusion Criteria: - mental disorder on Axis I - having already benefited from a family intervention such as psychoeducation - caring for several people with severe psychiatric disorders - receiving income for the caring activities - being legally responsible of the patient - having difficulty understanding fluent French - illiterate

Study Design


Related Conditions & MeSH terms


Intervention

Other:
control group
The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
Intervention group
The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.

Locations

Country Name City State
France Hopital Vinatier Bron

Sponsors (1)

Lead Sponsor Collaborator
Hôpital le Vinatier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in the severity of caregiver burden between V1 and V4 by the Zarit Burden Inventory scale (ZBI) The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden. A score of 17 or more was considered high burden. one year
Secondary Changes in caregiver burden severity at V1,V2 and V3 by the Zarit Burden Inventory (ZBI) scale The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden. A score of 17 or more was considered high burden. 8 months
Secondary Evolution of the caregivers' perceived-stress between V1, V2, V3, V4 by the Perceived Stress Scale-14 (PSS-14) Total score of the PSS can be obtained by summing the 14 items' scores . The total score ranges from 0 to a maximum of 56, a higher score indicating a higher level of perceived stress. one year
Secondary Evolution of the caregivers' mood between V1, V2, V3, V4 by the Center for Epidemiologic Studies-Depression Scale (CES-D) The CES-D consists of 20 items in a self-report format measuring depressive symptoms experienced in the past week on a 4-point Likert scale ranging from 0 (rarely or none of the time) to 3 (most or all of the time).
Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. ... PHQ-9 score =10 had a sensitivity of 88% and a specificity of 88% for major depression.
one year
Secondary Evolution of the caregivers' family functioning between V1, V2, V3, V4 Assessed by the Family Assessment Device scale (FAD) one year
Secondary Evolution of the caregivers' quality of life between V1, V2, V3, V4 Assessed by the Schizophrenia CareGiver Quality of Life scale (S-CGQoL) one year
Secondary Evolution of the caregivers' sense of competence between V1, V2, V3, V4 assessed by the Sense of Competence Questionnaire scale (SCQ) one year
Secondary Evolution of the caregivers' number of consultations with the general practitioner (GP) Change in number of consultations with the general practitioner (GP) n the 12 months prior to inclusion compared to the 12 months following inclusion 12 months period before baseline assessment versus 12 months period after baseline assessment
Secondary Evolution of the caregivers' number of days off work Change in number the caregivers' number of days off work in the 12 months prior to inclusion compared to the 12 months following inclusion 12 months period before baseline assessment vs. 12 months period after baseline assessment
Secondary Evolution of the caregivers' number of days on long-term leave or disability Change in the number of long-term leaves of absence or disability related to the caregiver situation in the 12 months prior to inclusion compared to the 12 months following inclusion 12 months period before baseline assessment vs. 12 months period after baseline assessment
Secondary Evolution of the caregivers' number of work days Change in the number of work days related to the caregiver situation in the 12 months prior to inclusion compared to the 12 months following inclusion 12 months
Secondary Evolution of the caregivers' willingness to pay someone to replace them in their caring activities during one hour Change in caregivers' willingness to pay someone to replace them in their caregiving activities for one hour in the 12 months prior to inclusion versus 12 months after inclusion. 12 months
Secondary Evolution of the caregivers' number of suicide attempts assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) The Columbia Suicide Severity Rating Scale (C-SSRS) is a measure used to identify and assess individuals at risk for suicide. Questions are phrased for use in an interview format, but can be completed as a self-report measure if necessary.
The score is created at each assessment for each patient and is used for determining treatment emergence. Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the C- SSRS) present at the assessment. Assign a score of 0 if no ideation is present.
12 months period before baseline assessment vs. 12 months period after baseline assessment
Secondary caregivers' satisfaction questionnaire 12 months
Secondary Evolution of the caregivers' living status (shared or non-shared household) between V1, V2, V3, V4 questionnaire 12 months
Secondary Evolution of the caregivers' informal caregiving activities between V1, V2, V3, V4 questionnaire 12 months
Secondary Evolution of the caregivers' number of hours spent providing informal caregiving between V1, V2, V3, V4 questionnaire 12 months
Secondary Evolution of the patients' psychotic symptoms severity between baseline and 12 months after baseline assessed by the Positive And Negative Syndrome Scale (PANSS) PANSS items are rated on a 7-point scale (1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, and 7=extreme); because the absence of symptoms is equal to 1 point, the lowest possible total score on both PANSS scales is 7. 12 months period before baseline assessment vs. 12 months period after baseline assessment
Secondary Evolution of the patients' functioning level between baseline and 12 months after baseline Assessed by the Global Assessment of Functionning scale (GAF) Baseline assessment and 12 months after baseline assessment
Secondary Evolution of the patients' functioning level assessed by the Personal and social Performance scale (PSP) The patient's degree of severity in the four domains is to be rated on a six-point scale from absent (which means no problems on this dimension) over mild, manifest, marked, severe to very severe difficulties in the given area. Out of the ratings on the four subdimensions, one total score on a 100-point scale can be created. A variation of eight points is already to be classified as a clinically relevant difference. The items "self-care" and "disturbing and aggressive behavior" are of greater concern for patients with acute Baseline assessment and 12 months after baseline assessment
Secondary Evolution of the patients' quality of life between baseline and 12 months after baseline Assessed by the Schizophrenia-quality of Life scale (S-QoL) Baseline assessment and 12 months after baseline assessment
Secondary Evolution of the patients' clinical severity between baseline and 12 months after baseline Assessed by the Clinical Global Impression (CGI) Baseline assessment and 12 months after baseline assessment
Secondary Evolution of the patients' depressive symptoms between baseline and 12 months after baseline Assessed by the Calgary Depression Scale for Schizophrenia scale (CDSS) Baseline assessment and 12 months after baseline assessment
Secondary Evolution of the patients' relapse risk factors between baseline and 12 months after baseline Composite score assessed by the Medication Adherence Rating Scale (MARS) and Birchwood Scale (Birchwood), substance use disorders (declarative questionnaire) Baseline assessment and 12 months after baseline assessment
Secondary Evolution of the patients' number of suicide attempts Assessed by the Columbia Suicide Severity Rating Scale " (C-SSRS) 12 months period before baseline assessment vs. 12 months period after baseline assessment
Secondary Evolution of the patients' suicide risk level Assessed by the Columbia Suicide Severity Rating Scale " (C-SSRS) Baseline assessment and 12 months after baseline assessment
Secondary Evolution of the patients' aggressive behaviors questionnaire 12 months period before baseline assessment vs. 12 months period after baseline assessment
Secondary Evolution of the patients' number of hospitalization in psychiatry number of hospitalization in psychiatry 12 months period before baseline assessment vs. 12 months period after baseline assessment
Secondary Evolution of the mental health professionals' beliefs and knowledge about psychoeducation to caregivers questionnaire Assessed before, after and 16 months after the training course
Secondary Evolution of the mental health professionals' sense of competence about psychoeducation to caregivers Self-assessment before, after and 16 months after the training course Assessed before, after and 16 months after the training course
Secondary Evolution of the mental health professionals' satisfaction of the training course questionnaire Assessed after and 16 months after the training course
Secondary Evolution of the mental health professionals' satisfaction of the BREF program questionnaire Assessed 16 months after the training course
Secondary Evolution of the psychiatric department organization regarding caregivers interventions questionnaire Assessed at baseline and 36 months after baseline
Secondary Sustainability of the BREF program in each psychiatric department Question the referent person at the center to know if the program is still used 3 years after its implementation
QUESTION THE REFERENT PERSON AT THE CENTER TO KNOW IF THE PROGRAM IS STILL USED 3 YEARS AFTER ITS IMPLEMENTATION
Question the referent perso of the center to know if the program is still used 3 years after its implementation
Assessed 36 months after baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A